Trupanion, Inc. (NASDAQ:TRUP - Get Free Report) COO John Gallagher sold 3,604 shares of Trupanion stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $29.70, for a total value of $107,038.80. Following the completion of the transaction, the chief operating officer owned 33,742 shares of the company's stock, valued at approximately $1,002,137.40. This trade represents a 9.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Trupanion Trading Down 4.4%
TRUP stock traded down $1.27 during midday trading on Tuesday, reaching $27.88. The company's stock had a trading volume of 400,520 shares, compared to its average volume of 630,232. Trupanion, Inc. has a 1 year low of $21.16 and a 1 year high of $46.98. The firm has a market capitalization of $1.22 billion, a price-to-earnings ratio of 52.60, a PEG ratio of 1.97 and a beta of 1.45. The stock has a fifty day simple moving average of $27.21 and a two-hundred day simple moving average of $25.89. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.77 and a current ratio of 1.77.
Trupanion (NASDAQ:TRUP - Get Free Report) last issued its earnings results on Wednesday, August 5th. The financial services provider reported $0.16 earnings per share for the quarter, beating analysts' consensus estimates of $0.11 by $0.05. The business had revenue of $392.93 million during the quarter, compared to analyst estimates of $389.72 million. Trupanion had a return on equity of 5.96% and a net margin of 1.53%.Trupanion's revenue was up 11.1% on a year-over-year basis. During the same period in the previous year, the company posted $0.22 EPS. On average, equities research analysts predict that Trupanion, Inc. will post 0.63 EPS for the current year.
Wall Street Analysts Forecast Growth
Several brokerages have weighed in on TRUP. Weiss Ratings upgraded shares of Trupanion from a "hold (c-)" rating to a "hold (c)" rating in a research note on Wednesday, August 26th. Zacks Research lowered shares of Trupanion from a "strong-buy" rating to a "hold" rating in a research note on Monday, August 24th. Stifel Nicolaus boosted their target price on shares of Trupanion from $28.00 to $29.00 and gave the company a "hold" rating in a research report on Thursday, August 20th. Piper Sandler downgraded Trupanion from an "overweight" rating to a "neutral" rating and cut their price target for the stock from $45.00 to $32.00 in a research report on Wednesday, August 26th. Finally, Atlantic Securities set a $42.00 price target on Trupanion in a research report on Wednesday, July 15th. One investment analyst has rated the stock with a Buy rating and five have issued a Hold rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $39.20.
Check Out Our Latest Stock Report on TRUP
Hedge Funds Weigh In On Trupanion
Several large investors have recently made changes to their positions in TRUP. Renaissancere Holdings Ltd. purchased a new position in Trupanion in the second quarter valued at $6,514,510. GSA Capital Partners LLP purchased a new position in shares of Trupanion in the 2nd quarter valued at about $1,394,000. Renaissance Technologies LLC increased its stake in shares of Trupanion by 550.0% in the 1st quarter. Renaissance Technologies LLC now owns 39,000 shares of the financial services provider's stock valued at $999,000 after purchasing an additional 33,000 shares in the last quarter. BlackRock Inc. acquired a new position in Trupanion in the 2nd quarter worth about $134,774,000. Finally, Dimensional Fund Advisors LP raised its holdings in Trupanion by 15.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 702,086 shares of the financial services provider's stock worth $17,981,000 after purchasing an additional 95,064 shares during the period.
About Trupanion
(
Get Free Report)
Trupanion, Inc is a pet medical insurance company that provides comprehensive insurance coverage for cats and dogs. The company's core offering is a single, customizable medical policy designed to cover veterinary diagnostic tests, surgeries, hospital stays and congenital or hereditary conditions. Trupanion seeks to streamline the claims process by offering direct payment options to participating veterinarians, reducing the need for upfront payments by pet owners.
Founded in 1999 by Darryl Rawlings and headquartered in Seattle, Washington, Trupanion began operations in the early 2000s and has grown its presence through both digital channels and partnerships with veterinary hospitals.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Trupanion, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Trupanion wasn't on the list.
While Trupanion currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.